RYZB Overview

RayzeBio inc is a company operating as vertically integrated radiopharmaceutical therapeutics company. The main objective of the company is defeating cancer with radiopharmaceutical medicines. It has a created a pipeline of multiple drug candidates, in therapeutic areas with significant market opportunities. They have a portfolio of potential RPT drug and development candidates that includes late-stage clinical programs, development programs and discovery programs.

Wall Street analysts forecast RYZB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RYZB is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

RayzeBio, Inc. revenue for the last quarter amounts to NaN USD, decreased % YoY.

RayzeBio, Inc.. EPS for the last quarter amounts to USD, decreased % YoY.

RayzeBio, Inc. (RYZB) has 88 emplpoyees as of February 10 2026.

Today RYZB has the market capitalization of 3.75B USD.